Author

Philip Onyebujoh

Observed names: ONYEBUJOH, P, Onyebujoh, P., P C Onyebujoh, P Onyebujoh, P. Onyebujoh, P.C. Onyebujoh, PC Onyebujoh, Philip C Onyebujoh, Philip C. Onyebujoh, Philip Chukwuka Onyebujoh, Philip C. Onyebujoh, Philip Chukwuka Onyebujoh

Institution: Lusaka Apex Medical University

Observed institutions: United Nations Development Programme, South African Medical Research Council, United Nations Children's Fund, Centers for Disease Control and Prevention, World Bank, Lusaka Apex Medical University, Centers for Disease Control and Prevention, Africa Centres for Disease Control and Prevention, World Health Organization, World Health Organization - Zimbabwe, African Union, World Health Organization Regional Office for Africa, United Nations Children's Fund India, Special Programme for Research and Training in Tropical Diseases, University College London

ORCID: 0000-0001-9194-2535

Observed ORCID: 0000-0001-9194-2535

OpenAlex ID: A5036624093

Laboratory medicine in low-income and middle-income countries: progress and challenges

2018 · John N Nkengasong, Katy Yao, et al. · The Lancet · 152

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial

2014 · Sayoki G Mfinanga, Bruce J Kirenga, et al. · The Lancet Infectious Diseases · 108

Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines

2012 · Helen McIlleron, Roxana Rustomjee, et al. · Antimicrobial Agents and Chemotherapy · 103

PDF

Treatment of tuberculosis: present status and future prospects.

2005 · Philip Onyebujoh, Alimuddin Zumla, et al. · Europe PMC (PubMed Central) · 97

Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

2015 · Maxwell T. Chirehwa, Roxana Rustomjee, et al. · Antimicrobial Agents and Chemotherapy · 86

Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa

1995 · P.C. Onyebujoh, T. Abdulmumini, et al. · Respiratory Medicine · 68

PDF

Advances in Immunotherapy for Tuberculosis Treatment

2009 · Gavin J. Churchyard, Gilla Kaplan, et al. · Clinics in Chest Medicine · 63

Drug resistant tuberculosis in Africa: Current status, gaps and opportunities

2018 · Nazir Ismail, Farzana Ismail, et al. · African Journal of Laboratory Medicine · 59

PDF

Treatment Options for HIV‐Associated Tuberculosis

2007 · Philip Chukwuka Onyebujoh, Isabela Ribeiro, et al. · The Journal of Infectious Diseases · 59

Treatment Strategies for HIV‐Infected Patients with Tuberculosis: Ongoing and Planned Clinical Trials

2007 · François‐Xavier Blanc, Diane V. Havlir, et al. · The Journal of Infectious Diseases · 53

Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

1999 · G Pillai, P B Fourie, et al. · PubMed · 52

Immunity against HIV/AIDS, Malaria, and Tuberculosis during Co-Infections with Neglected Infectious Diseases: Recommendations for the European Union Research Priorities

2008 · Diana Boraschi, Markos Abebe Alemayehu, et al. · PLoS neglected tropical diseases · 51

PDF

Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis

2017 · Maxwell T. Chirehwa, Helen McIlleron, et al. · Antimicrobial Agents and Chemotherapy · 46

PDF

TH1/TH2 switching and loss of CD4+ T cells in chronic infections: an immunoendocrinological hypothesis not exclusive to HIV

1993 · Graham A.W. Rook, Philip Onyebujoh, et al. · Immunology Today · 45

Laboratory medicine in Africa since 2008: then, now, and the future

2018 · John N Nkengasong, Francois-Xavier Mbopi-Keou, et al. · The Lancet Infectious Diseases · 43

PDF

Priorities in tuberculosis research

2006 · Philip Onyebujoh, William Rodriguez, et al. · The Lancet · 42

A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy.

1994 · G A Rook, P Onyebujoh, et al. · PubMed · 37

Sustainable clinical laboratory capacity for health in Africa

2017 · Justine Davies, Alash'le Abimiku, et al. · The Lancet Global Health · 33

PDF

Integrating laboratory networks, surveillance systems and public health institutes in Africa

2016 · Philip C. Onyebujoh, Ajay K. Thirumala, et al. · African Journal of Laboratory Medicine · 27

PDF

Response to the Ebola virus disease outbreak in the Democratic Republic of the Congo

2018 · John N Nkengasong, Philip Onyebujoh · The Lancet · 19

PDF

Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.

2004 · J L Johnson, A J Nunn, et al. · PubMed · 18

Efficacy and Safety of ‘Fixed Dose’ versus ‘Loose’ Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial

2016 · Abraham Aseffa, Joseph N. Chukwu, et al. · PLoS ONE · 16

PDF

Improving laboratory efficiencies to scale-up HIV viral load testing

2017 · George Alemnji, Philip Onyebujoh, et al. · Current Opinion in HIV and AIDS · 15

PDF

The WHO AFRO external quality assessment programme (EQAP): Linking laboratory networks through EQA programmes

2016 · Debrah I. Boeras, Rosanna W. Peeling, et al. · African Journal of Laboratory Medicine · 15

PDF

Mycobacterium vaccae immunotherapy

1991 · Anton Pozniak, J.L. Stanford, et al. · The Lancet · 15

Works count: 55

Citation count: 1,423

H-index: 19

I10-index: 28